Scientific article
Letter
Comment on "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US"
Published inAlzheimer's & dementia, vol. 21, no. 5, e70035
Publication date2025-05
First online date2025-05-12
Abstract
Keywords
- Alzheimer's disease
- Glucose‐lowering medications
- Methodological bias
- Prevention
- Semaglutide (Ozempic)
- Type 2 diabetes mellitus
Affiliation entities
Research groups
Citation (ISO format)
SALEHI-ABARGOUEI, Amin et al. Comment on ‘Associations of semaglutide with first-time diagnosis of Alzheimer’s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US’. In: Alzheimer’s & dementia, 2025, vol. 21, n° 5, p. e70035. doi: 10.1002/alz.70035
Main files (1)
Article (Published version)
Identifiers
- PID : unige:185121
- DOI : 10.1002/alz.70035
- PMID : 40356047
- PMCID : PMC12069008
Additional URL for this publicationhttps://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70035
Journal ISSN1552-5260
